Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has re-issued its Audit Report to correct the fiscal year end dates for its separate financial statements, reporting FY2025 consolidated revenue of KRW 4.56T and operating profit of KRW 2.07T with an ‘Unqualified’ audit opinion from KPMG Samjong Accounting Corp.
📊 [Key Disclosure Details & Financial Summary]
- Original Disclosure Date: 2026-03-26
- Amendment Date: 2026-03-26
- Reason for Amendment: Correction of clerical errors regarding separate financial statement fiscal year end dates
- Correction Details:
- Current Fiscal Year End Date: 2025-12-01 → 2025-12-31 (Corrected)
- Previous Fiscal Year End Date: 2024-12-01 → 2024-12-31 (Corrected)
- External Auditor & Audit Opinion:
- Auditor Name: KPMG Samjong Accounting Corp.
- Audit Report Receipt Date: 2026-02-25
- Audit Opinion: Unqualified / Clean (For both consolidated and separate statements)
- Adverse Internal Accounting Control System Opinion: Not Applicable
- Going Concern Uncertainty: Not Applicable
- Embezzlement or Breach of Trust Mentioned: No
- FY2025 Consolidated Financial Performance:
- Revenue: KRW 4.56T / KRW 4,556,971,695,180
- Operating Profit: KRW 2.07T / KRW 2,069,221,266,630
- Profit Before Income Tax: KRW 2.12T / KRW 2,118,631,252,684
- Net Profit: KRW 1.78T / KRW 1,784,352,060,593
- Net Profit Attributable to Owners of Parent: KRW 1.78T / KRW 1,784,352,060,593
- Total Assets: KRW 11.06T / KRW 11,060,741,976,837
- Total Liabilities: KRW 3.61T / KRW 3,609,631,328,852
- Total Equity: KRW 7.45T / KRW 7,451,110,647,985
- Capital Stock: KRW 115.7B / KRW 115,727,377,500
- Number of Consolidated Subsidiaries: 1
- FY2025 Separate Financial Performance:
- Revenue: KRW 4.56T / KRW 4,556,971,695,180
- Operating Profit: KRW 2.07T / KRW 2,068,092,839,427
- Net Profit: KRW 1.59T / KRW 1,586,186,963,312
- Total Assets: KRW 11.02T / KRW 11,023,968,735,616
- Total Liabilities: KRW 3.61T / KRW 3,608,519,898,043
- Total Equity: KRW 7.42T / KRW 7,415,448,837,573
- Other Key Notes:
- Financial statements in this audit report are subject to final approval at the annual general meeting of shareholders.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Final Approval of Financial Statements at the Annual General Meeting of Shareholders
This filing is a correction disclosure to amend clerical errors in the fiscal year end dates of separate financial statements in the audit report. Confirming whether the financial statements presented in this audit report are approved without alterations at the annual general meeting of shareholders is important for verifying the finalized financial results. Details can be verified in the upcoming annual report and shareholder meeting result disclosures.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
